Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma

Participants needed: 120
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.Updated: Feb 9, 2026Locations: 2
Eligibility criteria

Subjects participate voluntarily and sign informed consent. [+5]

Histologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like h... [+5]

Read more
Status: Recruiting

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors

Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.Updated: Feb 5, 2026Locations: 1
Eligibility criteria

(1) Age≥18 years old at the time of informed consent, male or female; [+11]

(1) Prior exposure to any CD47 antibody, SIRPα antibody, or CD47/SIRPα recombina... [+19]

Read more
Status: Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.

Participants needed: 242
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.Updated: Oct 12, 2023Locations: 1
Eligibility criteria

Male or female, aged at least 18 years, younger than 75 years. [+19]

Patients with unresectable or metastatic lesions, residual lesions after surgery... [+22]

Read more